Table 1.
Loss To Attrition.
| T1 | T2 | T3 | |
|---|---|---|---|
| N = 403 | N = 114 | N = 403 | |
| Visual Inspection with Acetic Acid (VIA) | |||
| Yes | 403 (100%) | 13 (11%) | 87 (21.6%) |
| VIA Positive | 124 (30.8%) | 4 (3.5%) | 7 (8.0%) |
| Cryotherapy | 114 (92%) | – | – |
| VIA Negative | 279 (69.2%) | 9 (7.9%) | 80 (92%) |
| Ineligible | 0 (0%) | 1 (0.9%) | |
| No | 0 (0%) | 33 (29%) | 79 (19.6%) |
| Loss to Follow-Up | – | 68 (60%) | 237 (58.8%) |
| Pap Smear | |||
| Yes | 183 (45.4%) | 30 (26.3%) | 96 (23.8%) |
| Pap Positive | 49 (12.2%) | 11 (36.7%) | 14 (14.6%) |
| Pap Negative | 134 (33.3%) | 19 (63.3%) | 77 (80.0%) |
| No | 199 (49.4%) | 21 (18.4%) | 57 (14.1%) |
| Loss to Follow-Up | 21 (5.2%) | 63 (55.3%) | 248 (61.5%) |
* VIA is the abbreviation for Visual Inspection with Acetic Acid.
† Time 1 (T1) is program implementation, Time 2 (T2) is 6 month follow-up for those who received cryotherapy at T1, Time 3 (T3) is 1-year follow-up for all those who were screened at T1.